News
15 August 2025

UICC welcomes Natasha Madsen Shah as new Executive Director of the ATOM Coalition

Natasha Shah brings over two decades of oncology and global health leadership to her new role, dedicated to expanding access to cancer medicines in underserved regions.

UICC is pleased to announce the appointment of Natasha Shah as the new Executive Director of the Access to Oncology Medicines (ATOM) Coalition, effective 18 August 2025.

Natasha brings over 20 years of leadership experience across academia, the pharmaceutical industry, and global health institutions, with a deep commitment to improving access to essential medicines for vulnerable populations, particularly in low- and lower-middle-income countries.

"On behalf of UICC and our partners across the ATOM Coalition, I warmly welcome Natasha as Executive Director. Her expertise and global perspective will be invaluable as the Coalition continues to address barriers to cancer care. We look forward to the energy and insight she will bring to our collective efforts."
– Cary Adams, CEO of UICC

Within the biotech/pharmaceutical industry, Natasha has a track record for building and leading complex initiatives from the ground up, including directing operations for a large strategic partnership portfolio at Amgen. She has also worked on partnership strategies within the World Health Organization and most recently at the Gates Foundation, where she contributed to the vaccine market shaping strategy for Gavi's 2026-2030 strategic period.

Natasha's experience and vision will be instrumental in advancing the ATOM Coalition’s mission to increase access to quality cancer medicines and diagnostics in countries where the need is the greatest.

UICC also extends its sincere thanks to Dr Dan Milner, who has served as Executive Director since 2022. Under Dan's leadership, the ATOM Coalition has significantly expanded its global partnerships and strengthened its position as a collaborative platform addressing barriers to access in cancer care.

“We are deeply grateful to Dan who has been instrumental in establishing the ATOM Coalition as a leading voice in access to oncology medicines. We are delighted that Dan will continue to work closely with the Coalition as Senior Advisor for Diagnostics and Pathology.”
– Cary Adams, CEO of UICC
Tags ATOM Coalition Access to Medicines Essential medicines

Last update

Tuesday 19 August 2025

Share this page

Related content

Collage of different faces and people smiling

The UICC-led Access to Oncology Medicines (ATOM) Coalition has launched its first series of Health Financing Case Studies, providing insights into how low- and lower-middle-income countries (LLMICs) are financing cancer care – and where targeted adjustments can strengthen access to essential medicines and diagnostics.
Cary Adams, CEO of UICC presenting at the ATOM Coalition side event. A conference room filled with attendees seated in rows, facing a speaker at the front. The room features large windows allowing natural light, and a presentation screen displaying a colorful slide. The audience appears engaged, with a mix of individuals in business attire, some taking notes or looking at their devices. The setting has a modern design with wooden paneling and a professional atmosphere.

Marking three years of progress, UICC-led Access to Oncology Medicines (ATOM) Coalition reflects on key milestones expanding access to cancer medicines in low- and lower middle-income countries (LLMICs).